Genprex has partnered with Roche Diagnostics to validate TROP2 biomarkers for patient selection in non-small cell lung cancer trials, aiming to accelerate precision medicine and improve treatment outcomes.
Breakthrough Designation | 04/08/2026 | By News Bureau
Akeso Secures Fifth NMPA Breakthrough Designation for Ivonescimab
The breakthrough designation supports ivonescimab combined with chemotherapy for first-line treatment of advanced Biliary Tract Cancer (BTC), based on an ongoing phase-III study comparing it with durvalumab-based chemotherapy.
Breakthrough Designation | 07/02/2026 | By News Bureau | 320
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy